| Detailed information |
|---|
| CancerLivER ID | 2071 |
| Biomarker | 4-Phosphopantothenoylcysteine |
| Biomarker Name/Symbol (given in Publication) | 4-Phosphopantothenoylcysteine |
| Biomolecule | Metabolite |
| Subject | Mice |
| Degree of Validity | Potential predictive biomarkers in the drug hispidulin (5,7,4'-trihydroxy-6-methoxyflavone) groups; but not validated on human patient cohorts |
| Experimental Condition | Drug treated group v/s control group |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Downregulated |
| Level of significance | p < 0.05 |
| Source | Urine and Plasma |
| PMID | 27077962 |
| Type of Biomarker | Potential Predictive * |
| Pathway | pantothenate and CoA biosynthesis metabolism |
| Cohort | Ascitic hepatoma 22 (H22) cells of murine carcinoma were obtained from the Nanjing University of Chinese Medicine. |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | mice bearing neoplasm (H22) for hispidulin |
| Year of Publication | 2016 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |